Clinical Trials Logo

Clinical Trial Summary

This is a randomized, multicenter phase II study of pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma as assessed by 1 year disease free survival rate.


Clinical Trial Description

This is a randomized, multicenter phase II study of pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma as assessed by 1 year disease free survival rate. The investigators primary aim is to examine the safety and efficacy of pembrolizumab in both pre-operative treatment paradigms for esophageal/GEJ carcinoma. The specific rationale for the investigators study design is rooted in three unanswered questions: 1. does the addition of an immune check-point inhibitor (pembrolizumab) enhance the efficacy of cytotoxic therapy (chemotherapy with chemoradiation) as determined by response rates, nodal down-staging and 1 year disease free survival in comparison to historical controls, 2. what are the pathological effects of combining pembrolizumab with chemotherapy alone, and 3. what are the molecular (PD-L1 expression), immunological (TILs extent) and gene-expression signatures associated with the efficacy of pembrolizumab in the neoadjuvant setting. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02998268
Study type Interventional
Source Weill Medical College of Cornell University
Contact Sabrina Machado, RN
Phone 646-962-3378
Email [email protected]
Status Recruiting
Phase Phase 2
Start date March 7, 2017
Completion date July 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04159974 - RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus Phase 2
Completed NCT03015389 - Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma
Enrolling by invitation NCT04642690 - Nitrates and IL-8 in Barrett's Esophagus
Completed NCT02128243 - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Phase 2
Recruiting NCT04430738 - Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers Phase 1/Phase 2
Recruiting NCT03539822 - Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies Phase 1/Phase 2
Terminated NCT03223662 - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy Phase 2
Active, not recruiting NCT01970306 - Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material Phase 2
Recruiting NCT04089904 - Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma Phase 2
Recruiting NCT02962063 - Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer Phase 1/Phase 2
Recruiting NCT02606396 - Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer N/A
Completed NCT02610764 - Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC N/A
Terminated NCT00430027 - Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma N/A
Active, not recruiting NCT00964080 - Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma Phase 1/Phase 2
Recruiting NCT04499924 - Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer Phase 2/Phase 3
Completed NCT02075905 - Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management N/A
Completed NCT03526328 - DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma
Recruiting NCT04900818 - Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT04295811 - Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC N/A
Recruiting NCT04150640 - P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric Phase 2